2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2090

The Effects of Commercially Available Footwear On Foot Pain and Disability in People With Gout: A Feasibility Study
Abstract Number: 1239

The Effects Of Hyperparathyroidism On Body Mass Index and Bone Mineral Density- An Observational Case-Control Study
Abstract Number: 1221

The Effects Of Hyperthyroidism On Bone Mineral Density At Different Sites- An Observational Case-Control Study
Abstract Number: 1082

The Effects of Prolotherapy in Patients With Subacromial Impingement Syndrome
Abstract Number: 1454

The Effects Of The Spleen Tyrosine Kinase Inhibitor Fostamatinib On Ambulatory Blood Pressure In Patients With Active Rheumatoid Arthritis – Results Of The Oskira Ambulatory Blood Pressure Monitoring Trial
Abstract Number: 464

The Efficacy and Safety Of Tocilizumab Subcutaneous Versus Tocilizumab Intravenous, In Combination With Traditional Dmards In Patients With RA At 49 Weeks (SUMMACTA)
Abstract Number: 1446

The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate
Abstract Number: 293

The Efficacy Of Etanercept In Patients With Juvenile Idiopathic Arthritis With Inadequate Response To Infliximab As a First TNF Inhibitor
Abstract Number: 2847

The Employment Experience Of People With Arthritis: Findings From An On-Line Survey
Abstract Number: 930

The Endocannabinoid Anandamide Modulates Adhesion, Proliferation and The Production Of Inflammatory Mediators In Rheumatoid Arthritis Synovial Fibroblasts By Activating CB₁, TRPV1, TRPA1 and Non-Cannabinoid Receptor Targets
Abstract Number: 2510

The Epidemiology Of Systemic LUPUS Erythematosus and Clinical Features Of Patients At A Single Center In Northwestern Turkey
Abstract Number: 2283

The Evolving Use Of Biologic Monotherapy In Rheumatoid Arthritis and Its Impact On Patient Outcomes
Abstract Number: 1392

The Expression Of Proto-Oncogene Survivin Splicing Variant 2B In Synovial Tissues and Blood From Patients With Rheumatoid Arthritis
Abstract Number: 1971

The Four Finger Examination Technique Is Superior To The Standard Two Finger Technique To Detect Metacarpal Phalangeal Joint Swelling In Rheumatoid Arthritis – A Validation By Power Doppler Ultrasound
Abstract Number: 65

The Frequency Of Bone Marrow Oedema Adjacent To The Cruciate Ligament Peri-Entheseal Vascular Channels In Inflammatory and Degenerative Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].